Phase 3 trial in children with ataxia telangiectasia: erythrocyte-encapsulated dexamethasone sodium phosphate did not significantly change RmICARS score vs placebo at 6 months in the 83 aged 6-9 (difference -1.30, 95% CI -2.77 to 0.18; p=0.085). Adverse events were similar.
RCTn = 105
Russo et al. Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial